

Immunai

Noam Solomon, [Tali Raveh](#)

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Immunai is building a platform for derisking development decisions for immunomodulatory therapeutics. Immunai's platform deciphers the immune effect in health and diseases using unique immune multi-omic single-cell data foundation, advanced analytics and cutting-edge experimental immunology. Immunai's platform is applicable to most diseases, with a focus on cancer and autoimmunity.

o Core Technology What is the technology, its uniqueness, and its value proposition?

Immunai's offerings rely on its Immunodynamics Engine (IDE™), an AI-based framework for deriving immune insights and recommendations, coupled with AMICA - the world's largest cell-level clinical immune database. AMICA drives drug development recommendations and facilitates transfer learning of insights, which are then validated through advanced molecular assays. This vertical integration of capabilities allows us to generate novel, differentiated insights for discovery and development.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

We have > 30 partnerships with academic institutions and biopharma, for discovering and advancing novel therapeutics, including 5 of the top 15 pharma companies. We have built proprietary knowledge libraries and deep expertise in a variety of immune cell compartments, including T-cell and myeloid suppression. Our long-term vision is pan-immune, but we're focusing first on immuno-oncology and autoimmune diseases.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Immunai collaborates with leading biopharmaceutical companies and academic research institutions to derisk drug development decisions, focusing on clinical trial optimization and patient stratification. We work with over 30 partners including 5 of the top 15 pharma companies

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Immunai's next key milestone is to co-develop preclinical candidates together with biotechnology and biopharma companies. Immunai has focused its platform on supporting clinical decision-making, including dose justification and patient stratification, and is now expanding its capabilities to support preclinical decision-making and ph1 drug positioning.

